UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-KSB/A

(X)    Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange
       Act of 1934 for the annual period ended JUNE 30, 2002

( )    Transition Report Pursuant to Section 13 or 15(d) of the Securities
       Exchange Act of 1934
       For the transition period from _____________ TO ______________

For the fiscal year ended June 30, 2002
Commission file number 0-21271

                       SANGUI BIOTECH INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

              Colorado                                84-1330732

  (State or other jurisdiction of         (IRS Employer Identification Number)
    incorporation or organization)

  1508 Brookhollow Drive, Suite 354                      92705
                                                         -----

         Santa Ana, CA  92705                          (Zip Code)
(Address of principal executive offices)

Issuer's telephone number, including area code       (714) 429-7807

Securities registered under Section 12(g) of the Exchange Act:

                           Common Stock, no par value
                           --------------------------


SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report on Form  10-KSB/A to be signed on its
behalf by the undersigned hereunto duly authorized.

SANGUI BIOTECH INTERNATIONAL, INC.



Date: October 17, 2002             /s/ Wolfgang Barnikol
                                   -----------------------------------
                                   Wolfgang  Barnikol
                                   President  and  Director


<PAGE>


PART I
------

ITEM 4. Submission of matters to a vote of security holders

No matter was submitted to a vote of the Company's security holders during the
fourth quarter covered by this Report.
The Company encourages its shareholders to put forward shareholder  proposals to
be  submitted  to a vote of  security  holders in the course of a  shareholders'
meeting  to be held  in the  first  half  of  calendar  year  2003.  Shareholder
proposals should arrive at the company's  offices in Santa Ana,  California,  or
Witten, Germany, no later than November 11, 2002. Shareholder proposals arriving
later  than  this  date  will  be  adjourned  to be  submitted  to a  subsequent
shareholders' meeting.


<PAGE>


CERTIFICATION PURSUANT TO
18 U.S.C.SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Sangui BioTech International,  Inc. (the
"Company")  on Form  10-KSB/A the period ended June  30,2002,  as filed with the
Securities  and  Exchange  Commission  on the  date  hereof  (the  "Report"),the
undersigned  certifies,  pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d)
       of the Securities Exchange Act of 1934; and

(2)    The information  contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.


Date:    October 17, 2002                            /s/ Wolfgang Barnikol
                                                     ---------------------------
                                                     Wolfgang Barnikol
                                                     President and Director

                                  CERTIFICATION

The undersigned,  Prof. Dr. Dr. W. Barnikol,  Chief Executive  Officer and Chief
Financial Officer, certifies that:

       1.       I have  reviewed this  annual report on  Form 10-KSB/A of Sangui
Biotech International, Inc.

       2.       Based on  my  knowledge, this annual report does not contain any
untrue  statement of a material fact or omit to state a material fact  necessary
to make the  statements  made,  in  light  of  circumstances  under  which  such
statements  were made, not misleading with respect to the period covered by this
annual report; and

       3.       Based  on  my  knowledge, the  financial  statements,  and other
financial  information  included in this annual  report,  fairly  present in all
material respects the financial condition,  results of operations and cash flows
of the registrant as of, and for, the periods presented in this annual report.


Date:    October 17, 2002                      By:   /s/ W. Barnikol
                                                     ---------------------------
                                                     Prof. Dr. Dr. W. Barnikol,
                                                     Chief Executive Officer and
                                                     Chief Financial Officer